Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

March 27, 2015 3:05 AM ET


Company Overview of Cell>Point L.L.C.

Company Overview

Cell>Point L.L.C., a biopharmaceutical company, develops intra-nuclear universal molecular imaging and therapeutic products for the diagnosis, staging, treatment, and post therapy assessment of cancer, cardiovascular diseases, and infectious diseases. The company focuses on developing universal oncology, cardiology, stroke and diabetes molecular imaging agents, and intra-nuclear metallic therapeutics. It offers radiodiagnostic imaging and intra-nuclear therapeutic agents, and delivery systems for the administration of local regional radio/chemotherapy. The company also provides 99mTc-EC-G (oncology), a metabolic imaging agent used to diagnose hyper metabolic activity in cancer cells; 99mTc-E...

7120 East Orchard Road

Suite 350

Centennial, CO 80111

United States

Founded in 2001





Key Executives for Cell>Point L.L.C.

Chief Executive Officer, Founding Member, Managing Member and Founder
Age: 74
Founder, Founding Member, Managing Member and Chief Financial Officer
Founder, Managing Partner, Founding Member and Chief Technology Officer
Compensation as of Fiscal Year 2014.

Cell>Point L.L.C. Key Developments

Cell>Point L.L.C. Announces Encouraging Results from (99m) Tc--EC--G Phase 2a Trial in Evaluating Presence and Severity of Coronary Artery Disease

Cell>Point L.L.C. announced results from conclusion of its Phase 2a cardiovascular clinical study performed by Cardiovascular Imaging Technologies of Kansas City, Missouri. The study imaged patients with technetium-99m-labeled EthylenediCysteine-Glucosamine (99mTc-EC-G), Cell>Point's proprietary nuclear imaging product candidate, which is target specific for detecting the presence and extent of ischemia in patients with Coronary Artery Disease (CAD). The results from the Phase 1 and 2a studies show that 99mTc-EC-G has the potential to accurately diagnose myocardial ischemia (that is, decrease in blood flow and oxygen to heart muscle) in as little as 30 minutes post injection in patients studied at rest only. The multicenter Phase 2b trial will evaluate the diagnostic accuracy (sensitivity and specificity) of a 99mTc-EC-G study performed at rest only compared to a two-day 99mTc-Cardiolite rest/stress study to determine the presence, anatomical location, and severity of ischemia in patients with CAD. Diagnostic catheterization will be used as the standard of truth. Camargo Pharmaceutical Services of Cincinnati will perform the role of general manager over the clinical research and regulatory function for the study. Premier Research of Research Triangle Park, North Carolina, will continue their role as the clinical research organization for the study.

Similar Private Companies By Industry

Company Name Region
Tepha, Inc. United States
Gene-Fresh Technologies United States
Audeo Oncology, Inc. United States
BioParadox Inc. United States
Siva Therapeutics Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Cell>Point L.L.C., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at